TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · IEX Real-Time Price · USD
18.31
+0.16 (0.88%)
At close: Jul 2, 2024, 4:00 PM
18.20
-0.11 (-0.60%)
After-hours: Jul 2, 2024, 7:44 PM EDT
TG Therapeutics Employees
TG Therapeutics had 264 employees as of December 31, 2023. The number of employees increased by 38 or 16.81% compared to the previous year.
Employees
264
Change (1Y)
38
Growth (1Y)
16.81%
Revenue / Employee
$1,095,962
Profits / Employee
$156,049
Market Cap
2.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264 | 38 | 16.81% |
Dec 31, 2022 | 226 | -60 | -20.98% |
Dec 31, 2021 | 286 | 14 | 5.15% |
Dec 31, 2020 | 272 | 138 | 102.99% |
Dec 31, 2019 | 134 | 29 | 27.62% |
Dec 31, 2018 | 105 | 30 | 40.00% |
Dec 31, 2017 | 75 | 11 | 17.19% |
Dec 31, 2016 | 64 | 24 | 60.00% |
Dec 31, 2015 | 40 | 16 | 66.67% |
Dec 31, 2014 | 24 | 11 | 84.62% |
Dec 31, 2013 | 13 | 7 | 116.67% |
Dec 31, 2012 | 6 | 1 | 20.00% |
Dec 31, 2011 | 5 | 3 | 150.00% |
Dec 31, 2010 | 2 | -2 | -50.00% |
Dec 31, 2009 | 4 | 0 | - |
Dec 31, 2008 | 4 | -3 | -42.86% |
Dec 31, 2007 | 7 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
Envista Holdings | 12,800 |
Azenta | 3,500 |
Inari Medical | 1,300 |
Twist Bioscience | 919 |
GoodRx Holdings | 694 |
Progyny | 566 |
Amicus Therapeutics | 517 |
TGTX News
- 25 days ago - TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 5 weeks ago - TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 2 months ago - TG Therapeutics stock just rallied 30%: what happened? - Invezz
- 2 months ago - TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire